The effectiveness of cytoflavin in complex therapy of patients with the coronavirus infection COVID-19

Close metadata

OBJECTIVE

To study therapy, including a sequential course of the drug Cytoflavin, on the dynamics of neurological and general status in patients with new coronavirus infection COVID-19.

MATERIAL AND METHODS

47 patients with a new coronavirus infection COVID-19, admitted to the hospital and having a state of moderate severity, according to the criteria of the Interim Guidelines of the Ministry of Health of the Russia for the prevention, diagnosis and treatment of a new coronavirus infection (COVID-19, version 9 of 10.26.2020). Clinical and neurological research, laboratory and instrumental examination methods were used before and after the course of therapy.

RESULTS

When a sequential Cytoflavin regimen is used in patients with COVID-19 infection, along with standard therapy, a significant improvement in neurological and general status is observed, as well as a significant positive dynamics in the results of laboratory and instrumental research methods (markers of a systemic inflammatory response, hemostasis and oxygenation disorders), which indicates on the influence of the significant effect of Cytoflavin on the processes of inflammation and hypercoagulability in COVID-19 infection.

CONCLUSION

The use of the drug Cytoflavin in the complex therapy of patients with COVID-19 infection is pathogenetically justified and expedient. The data obtained make it possible to recommend the inclusion of Cytoflavin in the treatment protocols for patients with COVID-19 coronavirus infection to optimize therapy and improve the course and outcome of the disease, as well as a longer use of Cytoflavin and repeated courses of its use in patients with COVID-19 infection.

Keywords:

coronavirus infection

COVID-19

rehabilitation

Cytoflavin

recovery from COVID-19

Authors:

Ekusheva E.V.

Federal Research and Clinical Centre for Specialized Medical Care and Medical Technologies;
Belgorod State National Research University

SPIN RSCI: 8828-0015
Scopus AuthorID: 6507964640
ORCID: 0000-0002-3638-6094

Voitenkov V.B.

Pediatric Research and Clinical Center for Infectious Diseases

SPIN RSCI: 6190-6930
Scopus AuthorID: 55797978400
ORCID: 0000-0003-0448-7402

Rizakhanova O.A.

North-Western State Medical University named after I.I. Mechnikov

ORCID: 0000-0003-2812-5246

Received:

08.11.2021

Accepted:

09.11.2021

List of references:

Desforges M, Coupanec AL, Dubeau P, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12(1):14-20. https://doi.org/10.3390/v12010014
Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood — brain barrier. Neurobiology of Diseases. 2020;146:105131. https://doi.org/10.1016/j.nbd.2020.105131
Mori I. Transolfactory neuroinvasion by viruses threatens the human brain. Acta Virologica. 2015;59:338-349. https://doi.org/10.4149/av_2015_04_338
Singh AK, Bhushan B, Maurya A, et al. Novel coronavirus disease 2019 (COVID-19) and neurodegenerative disorders. Dermatologic Therapy. 2020;33(4):13591. https://doi.org/10.1111/dth.13591
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clinical Immunology. 2020;215:108427. https://doi.org/10.1016/j.clim.2020.108427
Belopasov VV, Yachou Y, Samoilova EM, Baklaushev VP. The nervous system damage in COVID-19. Klinicheskaya Praktika. 2020;11(2):60-80. (In Russ.). https://doi.org/10.17816/clinpract34851
Iqbal FM, Lam K, Sounderajah V, Clarke JM, et al. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinical Medicine. 2021;36:100899. https://doi.org/10.1016/j.eclinm.2021.100899
Jacobson KB, Rao M, Bonilla H, et al. Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clinical Infectious Diseases. 2021;73(3):826-829. https://doi.org/10.1093/cid/ciab103
Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nature Medicine. 2021;27(4):626-631. https://doi.org/10.1038/s41591-021-01292-y
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. MedRxiv. 2021: 2021.01.27.21250617. https://doi.org/10.1101/2021.01.27.21250617
Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. https://doi.org/10.1371/journal.pone.0240784
Desai AD, Boursiquot BC, Melki L, Wan EY. Management of arrhythmias associated with COVID-19. Current Cardiology Reports. 2020;23(1):2. https://doi.org/10.1007/s11886-020-01434-7
Kanjwal K, Jamal S, Kichloo A, Grubb BP. New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection. The Journal of Innovation in Cardiac Rhythm Management. 2020;11(11):4302-4304. https://doi.org/10.19102/icrm.2020.111102
Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with non-critical COVID-19 two months after symptoms’ onset. Clinical Microbiol and Infection. 2021;27(2):258-263. https://doi.org/10.1016/j.cmi.2020.09.052
Annweiler C, Sacco G, Salles N, et al. National French survey of Coronavirus disease (COVID-19) symptoms in people aged 70 and over. Clinical Infectious Diseases. 2021;72(3):490-494. https://doi.org/10.1093/cid/ciaa792
Hellmuth J, Barnett TA, Asken BM, et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. The Journal of Neurovirology. 2021;27(1):191-195. https://doi.org/10.1007/s13365-021-00954-4
Batty GD, Deary IJ, Luciano M, et al. Psychosocial factors and hospitalisations for COVID-19: Prospective cohort study based on a community sample. Brain, Behavior, and Immunity. 2020;89:569-578. https://doi.org/10.1016/j.bbi.2020.06.021
Almeria M, Cejudo JC, Sotoca J, et al. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain, Behavior, & Immunity — Health. 2020;9:100163. https://doi.org/10.1016/j.bbih.2020.100163
Gu Y, Zhu Y, Xu F, et al. Factors associated with mental health outcomes among patients with COVID-19 treated in the Fangcang shelter hospital in China. Asia-Pacific Psychiatry. 2021;13:e12443. https://doi.org/10.1111/appy.12443
Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. The Clinical Medicine (Lond). 2021;21(1):63-67. https://doi.org/10.7861/clinmed.2020-0896
Davido B, Seang S, Tubiana R, de Truchis P. Post-COVID-19 chronic symptoms: a postinfectious entity? Clinical Microbiology and Infection. 2020;26(11):1448-1449. https://doi.org/10.1016/j.cmi.2020.07.028
Goldstein DS. The extended autonomic system, dyshomeostasis and COVID-19. Clinical Autonomic Research. 2020;30(4):299-315. https://doi.org/10.1007/s10286-020-00714-0
Umapathi T, Poh MQW, Fan BE, et al. Acute hyperhidrosis and postural tachycardia in a COVID-19 patient. Clinical Autonomic Research. 2020;30(6):571-573. https://doi.org/10.1007/s10286-020-00733-x
Miglis MG, Prieto T, Shaik R, et al. A case report of postural tachycardia syndrome after COVID-19. Clinical Autonomic Research. 2020;30(5):449-451. https://doi.org/10.1007/s10286-020-00727-9
Saeed S, Tadic M, Larsen TH, et al. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. Journal of Hypertension. 2021;39(7):1282-1292. https://doi.org/10.1097/HJH.0000000000002819
Summary of ICD coding for COVID-19. https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-for-COVID-19-disease-outbreak
Temporary guidelines. Prevention, diagnosis and treatment of coronavirus infection (COVID-19). Version 12. (21.09.21). 2021;232. (In Russ.). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/%D0%92%D0%9C%D0%A0_COVID-19_V12.pdf
Fedin AI, Rumyantseva SA, Piradov MA, et al. Clinical efficacy of Cytoflavin in patients with chronic cerebral ischemia (multicenter, placebo-controlled, randomized trial. Vrach. 2007;4(12):29-34. (In Russ.).
Polunina AG, Osinovskaya NA, Gudkova AN, Guekht AB. Influence of cytoflavin on symptoms of asthenia, emotional disorders and autonomic regulation in patients with organic asthenic disorder. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;2:28-33 (In Russ.).
Shabanov PD, Mokrenko EV. Synthetic inducers of interferon in the treatment and prevention of acute inflammatory diseases of the upper respiratory tract. Poliklinika. 2015;3:117-120. (In Russ.).
Parfenov SA, Belov VG, Parfenov JuA. Dynamics of indicators of the functional state of the central nervous system in the operators of the Navy after a long working cycle while taking Cytoflavin. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(8):55-58. (In Russ.). https://doi.org/10.17116/jnevro20171178155-58
Parfenov YuA, Vasilevskaya MA, Parfenov SA, et al. Justification of indications for the use of biofeedback therapy and cytoflavin in the treatment of neurological complications of osteochondrosis among elderly patients. Georgian Medical News. 2018;283:89-96. (In Russ.).
Temporary guidelines. Prevention, diagnosis and treatment of coronavirus infection (COVID-19). Version 9. (26.10.20). 2020;236. (In Russ.). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf
Ekusheva EV. The role of succinate-containing drugs in the processes of neuroplasticity after ischemic stroke. Eksperimental’naya i Klinicheskaya Farmakologiya. 2018;8(81):37-44. (In Russ.). https://doi.org/10.30906/0869-2092-2018-81-8-37-44
Xie N, Zhang L, Gao W, et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduction and Targeted Therapy. 2020;5:227. https://doi.org/10.1038/s41392-020-00311-7
Heer CD, Sanderson DJ, Voth LS, et al. Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable of innate immunity. Metabolism. 2020;295(52):17986-17996. https://doi.org/10.1074/jbc.RA120.015138
Mehmel M, Jovanović N, Spitz U. Nicotinamide riboside-the current state of research and therapeutic uses. Nutrients. 2020;12(6):1616. https://doi.org/10.3390/nu12061616
Omran HM, Almaliki MS. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis. Journal of Infection and Public Health. 2020;13(9):1196-1201. https://doi.org/10.1016/j.jiph.2020.06.004
Badawy AA. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. Bioscience Reports. 2020;40(10):BSR20202856. https://doi.org/10.1042/BSR20202856
Haskó G, Kuhel DG, Németh ZH, et al. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. The Journal Immunology. 2000;164(2):1013-1019. https://doi.org/10.4049/jimmunol.164.2.1013
Welihinda AA, Kaur M, Raveendran KS, Amento EP. Enhancement of inosine-mediated A2AR signaling through positive allosteric modulation. Cell Signaling Technology. 2018;42:227-235. https://doi.org/10.1016/j.cellsig.2017.11.002

Close metadata